Hospital
Vanderbilt Coffee Hospital, LLC
Vanderbilt Coffee Hospital, LLC was paid $4.09M by Medicaid between Jan 2021 and Dec 2024, across 97 billing codes. Its largest line is 99284, emergency room visit (serious) — 29% of everything it billed.
33Billing provider infoVANDERBILT COFFEE HOSPITAL, LLC
TULLAHOMA, TN 37388
TULLAHOMA, TN 37388
33aNPI1831798719assigned 10/21/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.09M
24GClaims115,260
24DCodes billed97
24AFirst – last monthJan 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#45 of 71
Median peer was paid$6.96M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SIMMONS, ANGELA controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 41,348 | $1.23M | |
| 2022 | 34,270 | $1.32M | |
| 2023 | 23,325 | $852K | |
| 2024incomplete | 16,317 | $685K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 29% | 10,729 | 9,217 | $1.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 8,546 | 7,717 | $811K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 15% | 4,083 | 3,456 | $603K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 6.3% | 2,680 | 2,471 | $257K |
| 59025 | Fetal non-stress test | 4.6% | 504 | 359 | $190K |
| 71045 | Radiologic examination, chest; single view | 3.3% | 2,934 | 2,492 | $133K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.0% | 2,435 | 2,033 | $124K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 4,450 | 3,683 | $121K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 3,715 | 3,011 | $117K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.4% | 1,065 | 978 | $57K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 3,216 | 2,926 | $42K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,870 | 1,515 | $40K |
85 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 753 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,591 | $38K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 727 | $33K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 300 | $32K |
| 87631 | <1% | 327 | $28K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 510 | $23K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 303 | $22K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 488 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 230 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,708 | $15K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,581 | $14K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 588 | $14K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 234 | $12K |
| 80053 | Comprehensive metabolic panel | <1% | 5,574 | $8K |
| G0378 | Hospital observation service, per hour | <1% | 48 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,817 | $7K |
| 86900 | <1% | 204 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 72 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,426 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 55 | $3K |
| 80076 | <1% | 3,039 | $3K | |
| 83880 | <1% | 765 | $3K | |
| 87400 | <1% | 805 | $3K | |
| 84484 | <1% | 2,470 | $3K | |
| 81001 | <1% | 5,391 | $3K | |
| 83690 | <1% | 2,947 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 155 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,238 | $2K |
| 87430 | <1% | 790 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 30 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 29 | $2K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 248 | $2K |
| 86850 | <1% | 200 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,310 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 243 | $1K |
| 83735 | <1% | 1,697 | $1K | |
| 84702 | <1% | 113 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 37 | $1K |
| 81025 | <1% | 959 | $910.10 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 121 | $843.52 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 121 | $842.82 |
| 87807 | <1% | 249 | $802.99 | |
| 87081 | <1% | 582 | $758.91 | |
| 84703 | <1% | 424 | $752.64 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 136 | $724.50 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,150 | $723.57 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 587 | $674.50 |
| 82077 | <1% | 50 | $672.80 | |
| 86901 | <1% | 205 | $658.74 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $583.87 |
| 87420 | <1% | 136 | $504.77 | |
| 86780 | <1% | 159 | $478.45 | |
| 86803 | <1% | 157 | $467.09 | |
| 85610 | <1% | 886 | $463.00 | |
| 84439 | <1% | 83 | $448.00 | |
| 84144 | <1% | 94 | $434.48 | |
| 85027 | <1% | 349 | $433.33 | |
| 86762 | <1% | 152 | $429.88 | |
| 87529 | <1% | 60 | $428.56 | |
| 85730 | <1% | 541 | $404.70 | |
| J3490 | Unclassified drugs | <1% | 74 | $368.01 |
| 83655 | <1% | 38 | $347.58 | |
| 87340 | <1% | 157 | $324.01 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 32 | $291.74 |
| 85379 | <1% | 154 | $288.18 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,416 | $251.77 |
| 86696 | <1% | 65 | $240.43 | |
| 82550 | <1% | 240 | $239.89 | |
| 80061 | Lipid panel | <1% | 15 | $208.73 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 27 | $176.24 |
| 86695 | <1% | 65 | $162.74 | |
| 87040 | <1% | 107 | $148.16 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 229 | $110.72 |
| 85007 | <1% | 153 | $83.89 | |
| 82150 | <1% | 87 | $79.98 | |
| 85018 | <1% | 38 | $70.14 | |
| 83605 | <1% | 48 | $65.78 | |
| 87186 | <1% | 65 | $39.28 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 299 | $38.81 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 181 | $37.44 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 47 | $20.50 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 25 | $6.20 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 46 | $0.34 |
| J2704 | Injection, propofol, 10 mg | 0% | 35 | $0.00 |
| A9270 | Non-covered item or service | 0% | 131 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSIMMONS, ANGELA (VP - FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | $137.59M |
| Vanderbilt University Medical Center | Nashville, TN | $29.07M |
| Vanderbilt Bedford Hospital, LLC | Shelbyville, TN | $4.41M |
| Vanderbilt Bedford Hospital, LLC | Shelbyville, TN | $2.02M |
| Vanderbilt University Medical Center | Nashville, TN | $1.01M |
| Vanderbilt Bedford Hospital, LLC | Shelbyville, TN | $926K |
| Vanderbilt University Medical Center | Nashville, TN | $270K |
| Vanderbilt Bedford Hospital, LLC | Wartrace, TN | $157K |
| Vanderbilt Bedford Hospital, LLC | Shelbyville, TN | $127K |
| Vanderbilt Bedford Hospital, LLC | Unionville, TN | $123K |
| Vanderbilt University Medical Center | Nashville, TN | $27K |
| Vanderbilt Bedford Hospital, LLC | Shelbyville, TN | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.